| Daiichi Sankyo, Inc. |
65597050404 |
Vanflyta 17.7mg capsule 14 count |
Brand |
FDA |
2023-08-09 |
7644.0000 |
See attached |
None |
6033 |
1 |
1 |
None |
None |
None |
None |
In the U.S., an estimated 20,380 new cases of AML will be diagnosed in 2023. Up to 37% of newly diagnosed cases of AML have a FLT3 gene mutation and approximately 80% of these have FLT3-ITD mutations. The total estimated patient population is derived from these estimates provided by the American Cancer Society (https://www.cancer.org/cancer/types/acute-myeloid-leukemia/about/key-statistics.html) |
https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=707 |
| Daiichi Sankyo, Inc. |
65597050428 |
Vanflyta 17.7mg capsule 28 count |
Brand |
FDA |
2023-08-09 |
15288.0000 |
See attached |
None |
6033 |
1 |
1 |
None |
None |
None |
None |
In the U.S., an estimated 20,380 new cases of AML will be diagnosed in 2023. Up to 37% of newly diagnosed cases of AML have a FLT3 gene mutation and approximately 80% of these have FLT3-ITD mutations. The total estimated patient population is derived from these estimates provided by the American Cancer Society (https://www.cancer.org/cancer/types/acute-myeloid-leukemia/about/key-statistics.html) |
https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=706 |
| Daiichi Sankyo, Inc. |
65597051104 |
Vanflyta 26.5mg capsule 14 count |
Brand |
FDA |
2023-08-09 |
7644.0000 |
See attached |
None |
6033 |
1 |
1 |
None |
None |
None |
None |
In the U.S., an estimated 20,380 new cases of AML will be diagnosed in 2023. Up to 37% of newly diagnosed cases of AML have a FLT3 gene mutation and approximately 80% of these have FLT3-ITD mutations. The total estimated patient population is derived from these estimates provided by the American Cancer Society (https://www.cancer.org/cancer/types/acute-myeloid-leukemia/about/key-statistics.html) |
https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=709 |
| Daiichi Sankyo, Inc. |
65597051128 |
Vanflyta 26.5mg capsule 28 count |
Brand |
FDA |
2023-08-09 |
15288.0000 |
See attached |
None |
6033 |
1 |
1 |
None |
None |
None |
None |
In the U.S., an estimated 20,380 new cases of AML will be diagnosed in 2023. Up to 37% of newly diagnosed cases of AML have a FLT3 gene mutation and approximately 80% of these have FLT3-ITD mutations. The total estimated patient population is derived from these estimates provided by the American Cancer Society (https://www.cancer.org/cancer/types/acute-myeloid-leukemia/about/key-statistics.html) |
https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=708 |
| Dash Pharmaceuticals, LLC |
69339016803 |
Gefitinib 250mg |
Generic |
FDA |
2023-06-05 |
3995.0000 |
Marketed as a typical generic to wholesalers and distributors |
None |
12 |
None |
None |
None |
None |
None |
None |
Not Acquired, priced in line with other generic competitors in this low volume product |
None |
| Dr. Reddy's Laboratories, Inc. |
43598014206 |
Nelarabine Inj. 250mg/50mL 6's USA |
Generic |
FDA |
2023-01-12 |
3966.0000 |
None |
1 |
6000 |
None |
None |
None |
None |
None |
None |
1) Dr. Reddy’s did not acquire the product. 2) Dr. Reddy’s does not track the estimated number of patients to be prescribed a drug on a monthly basis, due, among other reasons, to the fact that this is a generic product with numerous other generics available. Dr. Reddy’s lacks sufficient information to determine the total number of patients who may be prescribed its product given, among other things, (i) the unknown size of the prospective patient population meeting the relevant criteria; (ii) the current existence of numerous other prescription drugs with the same active pharmaceutical ingredient; and (iii) the existence of numerous other prescriptions drugs to treat these same conditions. Estimate provided is the number of patients diagnosed with T-cell acute lymphoblastic leukemia. |
None |
| Dr. Reddy's Laboratories, Inc. |
43598004563 |
Sunitinib Malate Caps 12.5mg 28s |
Generic |
FDA |
2023-01-16 |
4151.0900 |
None |
1 |
6000 |
None |
None |
None |
None |
None |
None |
1) Dr. Reddy’s did not acquire the product. 2) Dr. Reddy’s does not track the estimated number of patients to be prescribed a drug on a monthly basis, due, among other reasons, to the fact that this is a generic product with numerous other generics available. Dr. Reddy’s lacks sufficient information to determine the total number of patients who may be prescribed its product given, among other things, (i) the unknown size of the prospective patient population meeting the relevant criteria; (ii) the current existence of numerous other prescription drugs with the same active pharmaceutical ingredient; and (iii) the existence of numerous other prescriptions drugs to treat these same conditions. Estimate provided is the number of patients diagnosed with gastrointestinal stromal tumors (GIST) per year. |
None |
| Dr. Reddy's Laboratories, Inc. |
43598004863 |
Sunitinib Malate Caps 50mg 28s |
Generic |
FDA |
2023-01-20 |
14452.9600 |
None |
1 |
6000 |
None |
None |
None |
None |
None |
None |
1) Dr. Reddy’s did not acquire the product. 2) Dr. Reddy’s does not track the estimated number of patients to be prescribed a drug on a monthly basis, due, among other reasons, to the fact that this is a generic product with numerous other generics available. Dr. Reddy’s lacks sufficient information to determine the total number of patients who may be prescribed its product given, among other things, (i) the unknown size of the prospective patient population meeting the relevant criteria; (ii) the current existence of numerous other prescription drugs with the same active pharmaceutical ingredient; and (iii) the existence of numerous other prescriptions drugs to treat these same conditions. Estimate provided is the number of patients diagnosed with gastrointestinal stromal tumors (GIST) per year. |
None |
| Dr. Reddy's Laboratories, Inc. |
43598004663 |
Sunitinib Malate Caps 25mg 28s |
Generic |
FDA |
2023-02-16 |
8302.2100 |
None |
1 |
6000 |
None |
None |
None |
None |
None |
None |
1) Dr. Reddy’s did not acquire the product. 2) Dr. Reddy’s does not track the estimated number of patients to be prescribed a drug on a monthly basis, due, among other reasons, to the fact that this is a generic product with numerous other generics available. Dr. Reddy’s lacks sufficient information to determine the total number of patients who may be prescribed its product given, among other things, (i) the unknown size of the prospective patient population meeting the relevant criteria; (ii) the current existence of numerous other prescription drugs with the same active pharmaceutical ingredient; and (iii) the existence of numerous other prescriptions drugs to treat these same conditions. Estimate provided is the number of patients diagnosed with gastrointestinal stromal tumors (GIST) per year. |
None |
| Dr. Reddy's Laboratories, Inc. |
43598023531 |
Cycloserine Capsules 250mg, 30s |
Generic |
FDA |
2023-03-30 |
2297.0000 |
None |
1 |
8300 |
None |
None |
None |
None |
None |
None |
Dr. Reddy’s does not track the estimated number of patients to be prescribed a drug on a monthly basis, due, among other reasons, to the fact that this is a generic product with numerous other generics available. Dr. Reddy’s lacks sufficient information to determine the total number of patients who may be prescribed its product given, among other things, (i) the unknown size of the prospective patient population meeting the relevant criteria; (ii) the current existence of numerous other prescription drugs with the same active pharmaceutical ingredient; and (iii) the existence of numerous other prescriptions drugs to treat these same conditions. The estimate provided is the number of pulmonary tuberculosis patients in the US. |
None |
| Dr. Reddy's Laboratories, Inc. |
43598064711 |
Treprostinil Injection 100 mg/20 mL (5 mg/mL), 20ml |
Generic |
FDA |
2023-04-20 |
5729.9400 |
None |
1 |
1000 |
None |
None |
None |
None |
None |
None |
1) This product was not acquired; 2) Dr. Reddy’s does not track the estimated number of patients to be prescribed a drug on a monthly basis, due, among other reasons, to the fact that this is a generic product with numerous other generics available. Dr. Reddy’s lacks sufficient information to determine the total number of patients who may be prescribed its product given, among other things, (i) the unknown size of the prospective patient population meeting the relevant criteria; (ii) the current existence of numerous other prescription drugs with the same active pharmaceutical ingredient; and (iii) the existence of numerous other prescriptions drugs to treat these same conditions. The estimate provided is based on the number of cases of pulmonary arterial hypertension in the US per year. |
None |
| Dr. Reddy's Laboratories, Inc. |
43598064911 |
Treprostinil Injection 20 mg/20 mL (1 mg/mL), 20ml |
Generic |
FDA |
2023-04-20 |
1145.9900 |
None |
1 |
1000 |
None |
None |
None |
None |
None |
None |
1) This product was not acquired; 2) Dr. Reddy’s does not track the estimated number of patients to be prescribed a drug on a monthly basis, due, among other reasons, to the fact that this is a generic product with numerous other generics available. Dr. Reddy’s lacks sufficient information to determine the
total number of patients who may be prescribed its product given, among other things, (i) the unknown size of the prospective patient population meeting the relevant criteria; (ii) the current existence of numerous other prescription drugs with the same active pharmaceutical ingredient; and (iii) the existence of numerous other prescriptions drugs to treat these same conditions. The estimate provided is based on the number of cases of pulmonary arterial hypertension in the US per year. |
None |
| Dr. Reddy's Laboratories, Inc. |
43598064811 |
Treprostinil Injection 200 mg/20 mL (10 mg/mL), 20ml |
Generic |
FDA |
2023-04-20 |
11459.8800 |
None |
1 |
1000 |
None |
None |
None |
None |
None |
None |
1) This product was not acquired; 2) Dr. Reddy’s does not track the estimated number of patients to be prescribed a drug on a monthly basis, due, among other reasons, to the fact that this is a generic product with numerous other generics available. Dr. Reddy’s lacks sufficient information to determine the total number of patients who may be prescribed its product given, among other things, (i) the unknown size of the prospective patient population meeting the relevant criteria; (ii) the current existence of numerous other prescription drugs with the same active pharmaceutical ingredient; and (iii) the existence of numerous other prescriptions drugs to treat these same conditions. The estimate provided is based on the number of cases of pulmonary arterial hypertension in the US per year. |
None |
| Dr. Reddy's Laboratories, Inc. |
43598064611 |
Treprostinil Injection 50 mg/20 mL (2.5 mg/mL), 20ml |
Generic |
FDA |
2023-04-20 |
2864.9700 |
None |
1 |
1000 |
None |
None |
None |
None |
None |
None |
1) This product was not acquired; 2) Dr. Reddy’s does not track the estimated number of patients to be prescribed a drug on a monthly basis, due, among other reasons, to the fact that this is a generic product with numerous other generics available. Dr. Reddy’s lacks sufficient information to determine the total number of patients who may be prescribed its product given, among other things, (i) the unknown size of the prospective patient population meeting the relevant criteria; (ii) the current existence of numerous other prescription drugs with the same active pharmaceutical ingredient; and (iii) the existence of numerous other prescriptions drugs to treat these same conditions. The estimate provided is based on the number of cases of pulmonary arterial hypertension in the US per year. |
None |
| Dr. Reddy's Laboratories, Inc. |
43598030823 |
Plerixafor Injection 24 mg/1.2mL 1s USA |
Generic |
FDA |
2023-11-28 |
1200.0000 |
None |
1 |
80550 |
None |
None |
None |
None |
None |
None |
1) Product was not acquired; 2) Dr. Reddy’s does not track the estimated number of patients to be prescribed a drug on a monthly basis, due, among other reasons, to the fact that this is a generic product with numerous other generics available. Dr. Reddy’s lacks sufficient information to determine the
total number of patients who may be prescribed its product given, among other things, (i) the unknown size of the prospective patient population meeting the relevant criteria; (ii) the current existence of numerous other prescription drugs with the same active pharmaceutical ingredient; and (iii) the existence of numerous other prescriptions drugs to treat these same conditions. The number provided is the estimate of people diagnosed with non-Hodgkin lymphoma in the US; and 3) Dr. Reddy’s Plerixafor was introduced to market on 11/28/2023. That is the date when the product was available for sale. The publicly available published date of 11/06/2023 is simply the date that the WAC pricing was listed with the pricing compendia. However, for generic products, listing of the WAC does not trigger the statute as that date is not the date that the product is available for sale. For purchases of this product, the drug was not available for sale in California until 11/28/2023. This was the same date that was filed in our 3-day reports, and the reports submitted to other states under their drug price transparency statutes, as well as the date for purposes of computing government price reporting. |
None |